Loading news...
As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.03 per share a year ago.
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025.
Anika Therapeutics Inc. (NASDAQ: ANIK - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $9.41 and traded as high as $10.59. Anika Therapeutics shares last traded at $10.52, with a volume of 80,299 shares traded. Analyst Upgrades and Downgrades A number
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2025, Anika issued a press release announcing topline results from its clinical trial of Hyalofast,.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2025, Anika issued a press release announcing topline results from its clinical trial of Hya.
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Connor Clark and Lunn Investment Management Ltd. raised its holdings in Anika Therapeutics Inc. (NASDAQ: ANIK) by 24.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,994 shares of the biotechnology company's stock after buying an additional 8,573 shares during the
Anika Therapeutics, Inc. ( ANIK ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Matt Hall Cheryl Blanchard - President, CEO & Director Stephen Griffin - Executive VP, CFO & COO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Anika's third quarter earnings conference call. [Operator Instructions] I will now turn the call over to Matt Hall, Director, Corporate Development and Investor Relations.
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.25 per share a year ago.
Commercial Channel revenue up 22% with continued strong Integrity ™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the third quarter ended September 30, 2025.
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ: ANIK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $9.15, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.